Merck
This article was originally published in The Tan Sheet
Executive Summary
Douglas Greene, MD, named to the newly created position of Exec VP-Clinical Sciences & Product Development, overseeing the research lab division's drug development process, including clinical, regulatory, biostatistics and project planning and management functions. Greene served on FDA's Endocrinologic & Metabolic Diseases Advisory Committee between 1994 and 1998, where he helped analyze the NDA for Merck's Zocor cholesterol-lowering agent. Senior VP-Clinical & Regulatory Affairs Eve Slater, MD, who oversees Merck Rx-to-OTC switches, will report to Greene. Merck is examining the switch potential of its cholesterol-lowering drug Mevacor (1see story, p. 3)
You may also be interested in...
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands